Novo Nordisk launches new insulin therapy

BANGALORE: In a bigger step towards diabetes care, Novo Nordisk on Monday, launched two insulin analogues NovoMix 30 and NovoRapid after 20 years of research. The former is premixed while the latter is a rapid acting analogue.
Insulin analogues are genetically engineered products in which human molecules are modified to enable safer insulin regimens.Both these analogues will enhance options in insulin therapy for patients even as they reduce complications.
``The introduction of the analogues is another step in helping people with diabetes to better manage their glucose levels and facilitate a better lifestyle. It ensures a safer insulin regimen,'' Novo Nordisk, managing director, Sanjeev Shishoo said. The chief advantages of the analogues are better flexibility, higher efficacy and enhanced safety for patients. Patients can now aim for lower blood glucose control targets without the fear of hypoglycemia.
The analogues can be taken as two injections at mealtime for a good 24 hour control compared to the inconvenience due to the previous therapy requiring patients to take insulin injections half hour before meal time. The new analogues benefits come along with greater control of post meal sugar.
Novomix 30 and Novo Rapid are available in FlexPen-- an insulin delivery device.